Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
Barbara Jezeršek Novaković, Lučka Boltežar, Aleksander NovakovićDivision of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, 1000, SloveniaCorrespondence: Barbara Jezeršek NovakovićDivision of Medical Oncology, Institute of Oncology Ljubljana, Zaloška 2,...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-03-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/current-opinion-on-pixantrone-in-the-treatment-of-non-hodgkin-b-cell-l-peer-reviewed-article-TCRM |
| _version_ | 1818750491104903168 |
|---|---|
| author | Jezeršek Novaković B Boltežar L Novaković A |
| author_facet | Jezeršek Novaković B Boltežar L Novaković A |
| author_sort | Jezeršek Novaković B |
| collection | DOAJ |
| description | Barbara Jezeršek Novaković, Lučka Boltežar, Aleksander NovakovićDivision of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, 1000, SloveniaCorrespondence: Barbara Jezeršek NovakovićDivision of Medical Oncology, Institute of Oncology Ljubljana, Zaloška 2, Ljubljana, 1000, SloveniaTel +38615879631Fax +38615879305Email bjezersek@onko-i.siAbstract: Not many treatment options exist for patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in whom first- and second-line therapies were unsuccessful. This is especially true for patients with aggressive lymphomas. The innovative agent pixantrone has shown some promising results in terms of disease-free and overall survival, both in monotherapy as well as in combinations. However, recent trials (Phase III and real-world studies) reported unsatisfactory results, thereby raising the question about the role of pixantrone in the current treatment of R/R aggressive lymphomas. Nonetheless, there might still be a potential position for this drug in combinations, for use as first-line treatment of patients with cardiac dysfunction. This article summarizes the definition, structure, mechanism of action and reduced cardiotoxicity of pixantrone as well as efficacy and toxicity both in monotherapy and in combinations, as treatment for aggressive and indolent non-Hodgkin lymphomas.Keywords: pixantrone, B-cell non-Hodgkin lymphomas, efficacy, toxicity |
| first_indexed | 2024-12-18T04:20:31Z |
| format | Article |
| id | doaj.art-a7a07d97bfa349708902b90ce5f124bc |
| institution | Directory Open Access Journal |
| issn | 1178-203X |
| language | English |
| last_indexed | 2024-12-18T04:20:31Z |
| publishDate | 2021-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-a7a07d97bfa349708902b90ce5f124bc2022-12-21T21:21:15ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2021-03-01Volume 1718319262694Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell LymphomaJezeršek Novaković BBoltežar LNovaković ABarbara Jezeršek Novaković, Lučka Boltežar, Aleksander NovakovićDivision of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, 1000, SloveniaCorrespondence: Barbara Jezeršek NovakovićDivision of Medical Oncology, Institute of Oncology Ljubljana, Zaloška 2, Ljubljana, 1000, SloveniaTel +38615879631Fax +38615879305Email bjezersek@onko-i.siAbstract: Not many treatment options exist for patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in whom first- and second-line therapies were unsuccessful. This is especially true for patients with aggressive lymphomas. The innovative agent pixantrone has shown some promising results in terms of disease-free and overall survival, both in monotherapy as well as in combinations. However, recent trials (Phase III and real-world studies) reported unsatisfactory results, thereby raising the question about the role of pixantrone in the current treatment of R/R aggressive lymphomas. Nonetheless, there might still be a potential position for this drug in combinations, for use as first-line treatment of patients with cardiac dysfunction. This article summarizes the definition, structure, mechanism of action and reduced cardiotoxicity of pixantrone as well as efficacy and toxicity both in monotherapy and in combinations, as treatment for aggressive and indolent non-Hodgkin lymphomas.Keywords: pixantrone, B-cell non-Hodgkin lymphomas, efficacy, toxicityhttps://www.dovepress.com/current-opinion-on-pixantrone-in-the-treatment-of-non-hodgkin-b-cell-l-peer-reviewed-article-TCRMpixantroneb-cell non-hodgkin lymphomasefficacytoxicity |
| spellingShingle | Jezeršek Novaković B Boltežar L Novaković A Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma Therapeutics and Clinical Risk Management pixantrone b-cell non-hodgkin lymphomas efficacy toxicity |
| title | Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma |
| title_full | Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma |
| title_fullStr | Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma |
| title_full_unstemmed | Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma |
| title_short | Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma |
| title_sort | current opinion on pixantrone in the treatment of non hodgkin b cell lymphoma |
| topic | pixantrone b-cell non-hodgkin lymphomas efficacy toxicity |
| url | https://www.dovepress.com/current-opinion-on-pixantrone-in-the-treatment-of-non-hodgkin-b-cell-l-peer-reviewed-article-TCRM |
| work_keys_str_mv | AT jezerseknovakovicb currentopiniononpixantroneinthetreatmentofnonhodgkinbcelllymphoma AT boltezarl currentopiniononpixantroneinthetreatmentofnonhodgkinbcelllymphoma AT novakovica currentopiniononpixantroneinthetreatmentofnonhodgkinbcelllymphoma |